Impax Laboratories — Investor Presentation (February 2008)
30 slides from Impax Laboratories's investor presentation, Feb 7, 2008
Slide 1: IMPAX Laboratories Safe Harbor statement
IMPAX Laboratories, Inc. (IPXL.PK) "Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: To the extent any statements made in this presentation contain information that is not historical, these statements are forward-looking in nature and express the beliefs and expecta
Slide 2: 10-K Filing Timeline 2004-2007 Audits
10-K Filing Timeline 2004 - 2007 Audits 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q - -------------2005------------- ------------------2006------------------ --------------------2007---------------------2008------
Slide 3: Overview
Overview Technology-based specialty pharmaceutical company More than 140 R & D experts focused on formulating products that do not infringe on existing patents Generic - Concentration on First-to-File, First-to-Market opportunities Brand - 505 (b)(2) NDA Candidates focused on CNS Significant commerc
Slide 4: Technology and Drug Delivery Capabilities
Technology and Drug Delivery Capabilities Patented techniques and know-how Patents issued: United States - 7; Foreign - 11 Pending applications: United States - 9; Foreign - 28 Substantial development experience - 110 products approved, pending or under development targeting over $30 billion in US p
Slide 5: R&D Highlights for 2007
R & D Highlights for 2007 Received 6 FDA approvals Final approvals for generic versions of: Corzide 40/5mg, 80/5mg Ditropan XL 5,10mg Xanax XR 0.5, 1, 2, 3mg Lopid 600mg Persantine Tabs 25, 50, 75mg Baclofen Tabs 10, 20mg
Slide 6: Commercial Highlights for 2007
Commercial Highlights for 2007 Launched 5 new products Generic versions of: Colestid Tablets 1g Urecholine 5, 10, 25, 50mg Ditropan XL 5, 10mg Corzide 40/5mg, 80/5mg Persantine Tabs 25, 50, 75mg
Slide 7: Research and Development Strategy
Research and Development Strategy
Slide 8: Formulation Expertise Applied Technology Candidates
Formulation Expertise Applied Technology Candidates Generic Products First-to-File First-to-Market Limited Competition Products Branded Products CNS Products
Slide 9: Technology
Technology State-of-the art formulation techniques Diverse oral-solid formulation capabilities Targeting products with limited competition Controlled release projects where our substantial experience allows us to formulate around existing patents Specialty formulation projects where we focus on diff
Slide 10: Outsourced Product Development
Outsourced Product Development Complements (and leverages) internal programs Directed programs 4 offshore companies 13 projects outsourced 6 already submitted and 2 approved
Slide 11: Substantial and Growing Manufacturing Capacity
Substantial and Growing Manufacturing Capacity Hayward operations 1.2 billion unit annual capacity Taiwan plant underway Initial phase - 50% increase Fully approved and operational early 2010
Slide 12: Taiwan Construction
Taiwan Construction $25 million capital budget All production for export to the US Will be one of only a few FDA approved dosage form plants in Asia
Slide 13: Generic Target Market
Generic Target Market Immediate Release Immediate Release Controlled Release Controlled Release Total Total # Market # Market # Market Pending at FDA 10 $758 13 $9,447 23 $10,205 Under Development 15 $3,365 31 $12,906 46 $16,271 Total 25 $4,123 44 $22,353 69 $26,476 Market - US Market size in millio
Slide 14: Controlled Release Development Market
February 2008, Controlled Release — \ ir, 25 GDM IMPAX \, Development, $16,271
Slide 15: Paragraph-IV Generic Products Filings
Paragraph-IV Generic Products 26 Filings IMPAX Project Generic of* Est. Filing Order** Initial Filing Omeprazole 10,20,40mg DR Prilosec (AZN) 5th of 10 total 4Q99 Bupropion 100,150mg ER Wellbutrin SR (GSK) 3rd of 5 total 2Q00 Bupropion 150mg ER Zyban (GSK) 2nd of 4 total 2Q00 Fenofibrate 67,134,200m
Slide 16: Paragraph-IV Generic Products
Paragraph-IV Generic Products IMPAX Project Generic of* Est. Filing Order** Initial Filing Carbidopa/Levodopa ER Sinemet CR (BMS) 2nd of 4 total 4Q02 Carprofen 25,75 &100mg (Vet) Rimadyl (Pfizer) 1st of 2 total 4Q02 Bupropion 200mg ER Wellbutrin SR (GSK) 1st of 2 total 1Q03 Oxybutynin 5,10,15mg ER D
Slide 17: Paragraph-IV Litigation Status
Paragraph-IV Litigation Status Project Litigation Status Omeprazole 10, 20 & 40mg DR May 2007 trial court decision that Impax product infringes; patent not invalid. On appeal to the CAFC. Fexofenadine & PSE ER No trial date scheduled. Venlafaxine 37.5, 75, 150mg ER Trial expected 1Q 2008. Divalproex
Slide 18: Commercial Strategy
Commercial Strategy Competitive advantages - How we are different Broad-based Approach Multiple commercial outlets in uniquely diverse categories Customer focus Product selection - provide customers with generics that are somewhat unique Equally responsive to near-term customer needs and long-term c
Slide 19: Commercial Strategy: Primary Commercial Outlets
Commercial Strategy Primary Commercial Outlets: Global Pharmaceuticals Division (Generic) Highly experienced generic field sales organization currently supplying ALL major U.S. generic purchasers Fully integrated internal customer service organization; including electronic commerce (EDI, electronic
Slide 20: Commercial Strategy: Strategic Alliances
Commercial Strategy - -Strategic Alliances- Supplemental Commercial Outlets: TEVA - 12 products, 9 launched (only 22% of all 41 marketed products) DAVA - Oxycodone (OxyContin) 2nd Marketing period concluded Opportunistic Only if and when valuable
Slide 21: Global and Partnered Products
February 2008, Global and Partnered Products cl GD IMPAX
Slide 22: Brand Projects
Brand Projects (iD IMPAX
Slide 23: Brand Projects
Brand Projects Improved versions of marketed products Same R & D platform Clinical development Focused on CNS Smaller, more concentrated addressable market
Slide 24: VADOVA
VADOVA(tm) Value proposition Potentially higher patient compliance through reduced pill burden Received non-approvable letter January 2008 Nomenclature issues with the established name Evaluating options
Slide 25: Branded Products Pipeline
Branded Products Pipeline IPX056 Under clinical evaluation Clinical study targeted completion 2008 Data analysis and NDA submission target 2009 IPX066 and IPX111 clinical evaluations in 2008/2009
Slide 26: Brand Marketing and Sales
Brand Marketing and Sales 66 Reps calling on targeted neurologists with Carbatrol (Shire) $39 million funding through 6/2009 Relationships that will facilitate marketing future internal brand products with Impax
Slide 27: Significant Filing Milestones
Significant Filing Milestones *Includes amendments to two previously filed applications-not included in 2005 applications filed Filing Goal 2008: 8-10 with focus on controlled-release products 2000/ 2001 2002 2003 2004 2005 2006 2007 Applications Filed 16 8 8 6 10 6 7 PPG IV filings 9 5 4 1 3* 1 3 I
Slide 28: Financials
Financials Dec-06 = Mar.07 = Ju. 07 Sep-07 —_Dee.07(¢) (in thousands and unaudited) Cash and Investments $29,453 $47,071 $62,451 $142,152 $138,533 Long-Term Debt $89,600 $89,161 $86,527 $ 86,090 $ 82,760 Capital Expenditures $20,793 $6,269 $11,247 $15,686 $20,686 (Q2Months) Months) (Months) (9 Month
Slide 29: Strong Management Team
Strong Management Team Larry Hsu, Ph.D., President & CEO 30 years of experience, Abbott Laboratories, co-founded IMPAX David Doll, EVP Commercial Operations 20+ years of experience, Merck and Teva Arthur A. Koch, Jr., SVP, CFO 30 years of experience, Strategic Diagnostics, IBAH Inc., KPMG LLC Charle
Slide 30: Highlights
Highlights Broad-based drug delivery technology Strong product portfolio "Renewable" Strong management team Brand products offer long-term growth driver
Impax Laboratories — Investor Presentation (February 2008) on 6ix